1.
Clin Exp Dermatol
; 43(5): 573-576, 2018 Jul.
Artículo
en Inglés
| MEDLINE
| ID: mdl-29451318
RESUMEN
Omalizumab (Xolair® ) is an anti-IgE monoclonal antibody, which may benefit adults with systemic mastocytosis. We report effective treatment with omalizumab in two toddlers with severe diffuse cutaneous mastocytosis. Our cases offer preliminary evidence to support the safe use of omalizumab in paediatric patients with cutaneous mastocytosis.